Physician profile
Ronald T Ackerman
NPI 1942356621
$6,786.91
in general payments reported to CMS, 2019-2025
39 companies · $6,357 in 2025
The $6,357 reported for 2025 was more than what 94% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.16 · 2020: $89.60 · 2021: $33.99 · 2022: $22.99 · 2023: $164 · 2024: $59.39 · 2025: $6,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,235 · Travel and Lodging: $860 · Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,235.00 |
| Travel and Lodging | $859.92 |
| Food and Beverage | $485.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,412.26 | 2025 | |
| Genbiopro, INC. | $1,860.00 | 2025 | |
| Astellas Pharma US INC | $126.59 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $73.50 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Aspira Women'S Health INC | $45.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $37.62 | 2023 | Seglentis |
| Abbvie INC. | $36.91 | 2021-2022 | |
| Coopersurgical, INC. | $36.67 | 2020 | |
| Millicent US INC | $36.06 | 2024-2025 | Intrarosa, Femring |
| Dysis Medical, INC. | $34.17 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Bayer Healthcare Pharmaceuticals INC. | $20.81 | 2019 | |
| Evofem Biosciences, INC. | $20.07 | 2021 | |
| Exact Sciences Corporation | $18.72 | 2024 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $16.03 | 2023 | Balcoltra |
| Therapeuticsmd, INC. | $12.06 | 2019 |
24 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.